introduct
blood
donor
screen
viru
nucleic
acid
amplif
technolog
nat
mid
late
driven
socal
aid
hepat
c
viru
hcv
epidem
thousand
recipi
infect
blood
product
compon
plasma
fraction
first
introduc
nat
test
besid
pathogen
reduct
procedur
reduc
viru
transmiss
risk
product
achiev
similar
safeti
standard
nat
also
introduc
labil
blood
compon
german
transfus
centr
first
start
inhous
nat
test
donat
pool
sampl
hcv
hepat
b
viru
hbv
human
immunodefici
year
later
diagnost
industri
provid
commerci
hcv
later
hbv
nat
test
autom
platform
nat
test
hepat
viru
parvoviru
follow
driven
transfus
centr
inhous
test
sever
acut
respiratori
syndrom
corona
viru
sarscov
west
nile
viru
emerg
nat
enabl
manufactur
transfus
centr
instantli
introduc
sensit
specif
screen
test
subsequ
autom
includ
sampl
prepar
significantli
reduc
cost
complex
procedur
made
afford
middl
incom
countri
well
current
million
nation
per
year
nat
test
worldwid
remain
residu
risk
viru
transmiss
blood
compon
product
could
reduc
almost
zero
autom
render
possibl
reduct
pool
size
conjunct
increas
throughput
sensit
thu
antibodi
antigen
test
may
dispens
long
run
particularli
combin
nat
test
pathogen
reduct
new
technolog
horizon
like
digit
droplet
pcr
nextgener
sequenc
labonachip
digit
antigen
assay
compar
sensit
howev
limit
either
throughput
cost
autom
time
result
specif
need
nat
integr
part
technolog
thu
nat
still
shortest
effici
mean
result
donor
screen
nat
also
contribut
significantli
knowledg
fast
virus
replic
respect
diagnost
window
conjunct
anim
patient
studi
learn
minim
infecti
dose
epidem
donor
popul
polymeras
chain
reaction
pcr
invent
kari
mulli
honour
nobl
prize
still
relev
nucleic
acid
amplif
technolog
nat
comprehens
revolution
diagnost
mani
area
compar
altern
nat
exampl
transcriptionmedi
amplifica
tion
tma
pcr
could
easier
establish
inhous
mani
laboratori
worldwid
littl
effort
reason
cost
invent
realtim
pcr
technolog
becam
amen
autom
significantli
reduc
inher
drawback
contamin
equip
laboratori
amplif
product
amplicon
could
minim
even
elimin
intern
control
could
easili
includ
discrimin
target
sequenc
label
differ
fluorophor
multiplex
pcr
sever
differ
virus
could
detect
parallel
one
test
discrimin
differ
label
readili
avail
technolog
fuell
mani
applic
requir
highest
sensit
specif
conjunct
highest
throughput
reason
cost
technic
advanc
pave
way
past
decad
unpreced
high
level
blood
safeti
earli
data
accumul
indic
aid
infecti
diseas
caus
unknown
viru
prefer
spread
male
homosexu
commun
also
transmit
blood
blood
product
late
public
report
worldwid
identif
posttransfus
nonanonb
hepat
patient
high
rate
antibodi
newli
identifi
hepat
c
viru
hcv
similar
high
rate
observ
haemophiliac
alarm
data
trigger
studi
residu
risk
transfusiontransmit
hcv
hepat
b
viru
hbv
infect
germani
substanti
risk
per
transfus
blood
unit
report
seem
quit
low
accept
author
howev
percept
chang
germani
particularli
weekli
magazin
headlin
aid
scandal
deadli
blood
author
mention
alreadi
report
year
ago
risk
transmit
hiv
blood
product
critic
articl
issu
noth
happen
total
haemophiliac
hiv
infect
germani
situat
german
blood
transfus
field
seem
absurd
author
follow
public
awar
polit
discuss
farreach
consequ
congression
investig
committe
hiv
infect
blood
blood
product
establish
final
report
committe
state
infect
among
recipi
blood
blood
product
germani
could
prevent
nobodi
su
involv
feder
state
author
industri
health
insur
hospit
red
cross
perform
inadequ
list
recommend
suggest
increas
blood
safeti
relev
new
transfus
law
adopt
addit
modif
exist
german
medicin
law
paulehrlichinstitut
pei
establish
new
senior
feder
author
blood
blood
product
pei
collabor
german
medic
associ
releas
guidelin
defin
latest
standard
prevail
scienc
technolog
transfus
medicin
surveil
transfus
risk
implement
importantli
revers
evid
damag
compens
implement
german
medicin
law
recommend
adopt
motiv
manufactur
blood
establish
introduc
new
technolog
potenti
reason
increas
blood
safeti
cost
becam
secondari
sinc
hcvand
blood
product
distribut
worldwid
mani
countri
affect
hivcontamin
blood
product
even
knowingli
administ
haemophiliac
franc
patient
infect
usa
infect
itali
uk
spain
around
infect
respect
nat
test
batch
clot
factor
immunoglobulin
product
pool
reveal
high
hcv
contamin
rate
particularli
inactiv
find
promot
idea
test
donor
blood
nat
addit
antibodi
antigen
test
manufactur
process
begin
committe
proprietari
medicin
product
cpmp
push
hcv
nat
manufactur
plasma
pool
test
order
identifi
viruscontamin
batch
sourc
materi
manufactur
blood
product
distribut
worldwid
juli
batch
deriv
plasma
pool
test
found
nonreact
hcv
rna
nat
batch
releas
market
authoris
holder
detect
limit
assay
equival
run
control
hcv
rna
content
iuml
pretest
mini
pool
encourag
order
prevent
contamin
product
pool
thousand
litr
plasma
consequ
manufactur
implement
pretest
quit
larg
mini
pool
consist
sampl
hundr
donat
blood
establish
sell
plasma
fraction
provid
separ
plasma
sampl
pool
test
complic
logist
increas
cost
side
reduc
expenditur
manufactur
offer
higher
rate
plasma
pretest
nat
blood
centr
sell
plasma
fraction
therefor
interest
establish
inhous
nat
pretest
mini
pool
could
also
adopt
labil
compon
contrast
fraction
plasma
platelet
shelf
life
day
result
avail
pool
platelet
manufactur
thu
time
result
condens
less
work
day
consequ
pool
size
reduc
pool
resolut
acceler
smaller
pool
sampl
caus
increas
throughput
workload
cost
reduc
number
donat
hold
pool
test
posit
improv
blood
suppli
simplifi
platelet
product
importantli
reduct
pool
size
increas
sensit
product
safeti
howev
method
manual
cumbersom
logist
complic
commerci
assay
avail
sever
diagnost
compani
invit
blood
establish
collabor
appli
nat
assay
blood
donat
screen
argu
technolog
still
immatur
develop
cost
would
never
pay
back
initi
public
applic
inhous
approach
mini
pool
plasma
test
confirm
concern
matur
pcr
test
blood
bank
set
pcr
well
establish
patient
diagnost
howev
screen
thousand
healthi
mostli
neg
blood
donor
per
day
requir
quit
differ
approach
repeat
test
option
therefor
fals
neg
avoid
thu
screen
blood
donor
requir
highest
sensit
specif
highest
throughput
shortest
time
result
lowest
cost
altogeth
quit
challeng
use
direct
viru
detect
pcr
blood
donor
screen
alreadi
report
singl
donat
test
first
data
publish
routin
screen
mini
pool
donat
hcv
hbv
pcr
throughput
sampl
per
day
among
thousand
donat
test
neg
serolog
assay
hbv
hcv
posit
pcr
high
number
hcv
pcronli
posit
exceed
factor
estim
yield
rate
hcv
seronegativepcr
posit
donat
germani
accord
previou
public
howev
studi
perform
smaller
pool
sampl
report
virem
seroneg
donat
among
thousand
test
expect
number
first
data
demonstr
reliabl
feasibl
blood
donor
screen
pcr
publish
test
thousand
donat
pool
viru
enrich
simplifi
centrifug
test
hcv
hbv
two
hcv
natonli
posit
close
estim
rate
thousand
base
accumul
data
follow
cpmp
regul
sourc
plasma
pei
mandat
juli
hcv
nat
test
labil
blood
compon
germani
detect
limit
iuml
per
individu
donat
pei
wise
abstain
mandat
pool
size
blood
screen
intent
leav
open
field
differ
technolog
logist
approach
hbv
nat
mandat
time
despit
fact
pcr
screen
blood
donat
inhous
assay
three
transfusionrelev
virus
voluntarili
introduc
major
blood
establish
year
commerci
assay
hbv
avail
blood
bank
access
inhous
method
nat
mandat
germani
antihbc
test
hbv
nat
yet
envisag
mandatori
test
germani
demonstr
feasibl
efficaci
blood
donat
screen
inhous
assay
germani
diagnost
nat
test
manufactur
start
valid
assay
blood
screen
well
took
year
nat
test
hcv
introduc
countri
except
austria
blood
centr
sent
sampl
germani
test
fig
commerci
hbv
nat
assay
blood
screen
becam
avail
mani
year
later
fig
superior
sensit
pcr
result
seriou
drawback
highli
contamin
prone
amplicon
could
evad
laboratori
upon
open
vial
detect
laboratori
contamin
blood
suppli
danger
problem
could
solv
almost
complet
invent
realtim
pcr
enabl
detect
amplicon
without
open
reaction
tube
blood
bank
first
adopt
technolog
inhous
nat
realtim
pcr
also
pave
way
increas
degre
autom
notic
cost
reduct
technolog
progress
came
along
increas
regulatori
standard
process
intern
work
group
standard
genom
amplif
techniqu
sogat
establish
behalf
sinc
coordin
nation
institut
biolog
standard
control
nibsc
uk
group
focuss
develop
intern
standard
blood
screen
first
hcv
standard
nat
assay
establish
hbv
highest
measur
standard
intern
agre
arbitrari
unit
determin
intern
collabor
studi
panel
standard
continu
expand
transfusionrelev
virus
use
secondari
standard
run
control
assay
calibrationvalid
conjunct
genotyp
seroconvers
panel
contribut
current
high
standard
commerci
inhous
nat
assay
inhous
donor
screen
nat
remain
specif
german
approach
despit
increas
vitro
diagnost
regul
german
blood
centr
first
introduc
hcv
hbv
nat
first
introduc
hepat
viru
parvoviru
b
nat
soon
commerci
manufactur
abl
provid
test
kit
instrument
adapt
specif
requir
blood
bank
countri
follow
introduc
nat
test
fig
current
million
donat
per
year
test
worldwid
despit
continu
concern
costbenefit
ratio
nat
test
yield
seroneg
natonli
posit
donat
substanti
final
convinc
critic
highest
yield
expectedli
obtain
hcv
nat
accord
long
preseroconvers
window
explos
rampup
phase
high
plateau
phase
concentr
hcv
first
comprehens
data
nat
yield
report
germani
reveal
hcv
hbv
natonli
posit
among
million
test
donat
usa
hcv
natonli
posit
identifi
among
million
test
report
hbv
test
implement
usa
time
intern
societi
blood
transfus
isbt
work
parti
transfusiontransmit
infecti
diseas
wpttid
perform
intern
survey
nat
test
blood
donat
expand
implement
yield
data
countri
introduc
nat
test
collect
cover
million
donat
nat
test
sinc
introduct
within
tabl
despit
constantli
decreas
cost
increas
autom
german
blood
centr
prefer
test
donat
mini
pool
mainli
high
sampl
number
per
day
broad
rang
virus
test
justifi
substanti
extrem
low
rate
hcv
transmiss
observ
germani
sinc
nat
test
commenc
also
justifi
moder
nat
limit
detect
mandat
pei
hcv
iuml
per
individu
donat
respect
hcv
transmit
donat
low
viral
load
even
lod
sensit
singl
donat
test
kit
transmiss
howev
due
mutat
primerprob
bind
site
result
fals
neg
nat
test
result
sinc
surveil
reveal
mani
test
failur
germani
fortun
without
transmiss
pei
mandat
least
dual
target
nat
prevent
fals
neg
one
genom
region
would
mutat
primersprob
bind
howev
one
nat
compani
introduc
tripl
target
pcr
analys
nat
test
failur
identifi
two
new
clade
b
isol
highli
mutat
even
conserv
region
rais
concern
suffici
sequenc
coverag
two
independ
amplicon
impact
nat
test
blood
safeti
restrict
wellknown
transfusionrelev
virus
past
decad
new
virus
emerg
old
one
reemerg
vari
impact
blood
safeti
west
nile
viru
epidem
broke
new
york
reach
west
coast
hit
popul
thousand
infect
peopl
target
test
blood
donor
nat
rapidli
implement
combin
mini
pool
test
switch
sensit
singledon
test
first
reactiv
mini
pool
identifi
sinc
three
transmiss
occur
blood
compon
clearli
demonstr
high
contribut
nat
test
blood
safeti
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
china
novemb
first
report
februari
rapid
provis
sensit
specif
diagnost
test
utmost
import
halt
epidem
nat
test
could
instantli
develop
provid
patient
blood
donor
diagnost
end
outbreak
contain
recent
studi
reveal
high
percentag
hepat
e
viru
hev
infect
blood
donor
frequent
transmiss
viru
blood
compon
europ
mani
countri
worldwid
countri
alreadi
introduc
hev
nat
screen
blood
donat
includ
uk
ireland
netherland
recent
switzerland
germani
pei
intend
mandat
hev
nat
screen
octob
accord
phase
plan
underlin
import
nat
test
countermeasur
reduc
transmiss
risk
nat
test
mani
emerg
reemerg
virus
develop
suitabl
blood
screen
includ
cytomegaloviru
chikungunya
viru
dengu
viru
recent
zika
viru
case
outbreak
unknown
viru
nat
test
instantli
develop
soon
genom
sequenc
identifi
make
blood
safer
ever
blood
donat
nat
test
increas
blood
safeti
also
provid
insight
epidemiolog
natur
histori
pathogenesi
viral
infect
particular
knowledg
virus
replic
respect
diagnost
window
expand
analys
seroconvers
panel
obtain
frequent
sourc
plasma
donor
quantit
qualit
nat
reveal
long
preseroconvers
window
day
averag
high
replic
rate
hcv
doubl
time
h
similar
studi
perform
panel
hbv
infect
donor
reveal
doubl
time
day
respect
data
allow
estim
back
calcul
reduct
preseroconvers
window
nat
assay
residu
window
nat
test
depend
sensit
respect
test
blood
donat
nat
also
trigger
studi
minim
infecti
dose
differ
virus
direct
impact
blood
safeti
requir
lod
nat
test
reach
zero
risk
infecti
dose
calcul
revers
probit
analysi
viral
load
transmit
nontransmit
donat
result
minim
infecti
dose
virion
howev
consider
lower
concentr
found
infecti
minim
infecti
dose
hbv
assess
chimpanze
human
mous
model
good
accord
copi
hbv
dna
rampup
phase
caus
hbv
infect
inocul
chimer
mice
chimpanze
howev
sampl
taken
late
antibodi
hepat
b
core
antigen
antihbc
posit
tail
end
phase
less
infecti
hcv
minim
infecti
dose
determin
chimpanze
copi
frequent
occurr
chronic
occult
hbv
infect
either
antihbc
posit
neg
wellknown
donor
screen
reveal
acut
occult
hbv
infect
occur
well
donor
present
low
transient
hepat
b
viremia
hbsag
alt
neg
infecti
virem
phase
late
seroconvers
antihb
andor
antihbc
posit
observ
introduct
hcv
nat
hcv
antibodyantigen
combo
assay
antihbc
test
made
nonspecif
alt
test
superflu
regulatori
requir
discontinu
germani
debat
hbv
nat
replac
hbsag
test
sensit
hbv
nat
proven
interdict
effici
hbv
transmiss
preseroconvers
window
donat
antihbc
test
highli
sensit
suffici
specif
detect
chronic
occult
carrier
low
level
viremia
hbsag
test
simpli
doubl
screen
viru
obviou
advantag
sensit
compar
nat
test
discontinu
hbsag
test
would
save
money
sinc
hbv
nat
includ
commerci
nat
test
kit
design
blood
screen
cost
extra
scienc
technolog
advanc
rapidli
sinc
introduct
viru
nat
test
transfus
medicin
twenti
year
realtim
pcr
tma
introduc
blood
donat
screen
almost
complet
autom
cover
broad
panel
virus
test
parallel
residu
risk
transfusiontransmit
virus
reduc
nat
almost
zero
bacteria
becom
relev
challeng
pathogen
transfus
medicin
transmiss
rate
exceed
virus
order
magnitud
pathogen
reduct
measur
effect
virus
bacteria
well
howev
resist
virus
bacteria
reduc
entir
inactiv
nat
bacteria
would
requir
gener
nat
test
direct
highli
conserv
gene
howev
donor
screen
yet
feasibl
due
background
dna
bacteri
dna
present
air
water
particularli
dna
polymeras
prepar
deriv
bacteria
sequenc
contamin
pcr
reagent
coamplifi
therebi
impair
detect
limit
array
technolog
could
potenti
circumv
drawback
specif
detect
thousand
differ
gene
agent
exampl
transfusionrelev
virus
bacteria
one
sampl
howev
volum
process
tini
reduc
chanc
detect
small
copi
number
donor
sampl
earli
phase
infect
even
amplif
nat
preced
array
detect
increas
sensit
moreov
amplif
subsequ
array
detect
prolong
time
result
increas
cost
compar
shortcom
argu
nextgener
sequenc
ng
altern
nat
donat
screen
massiv
parallel
deep
sequenc
provid
access
whole
genom
whole
microbiom
singl
sampl
time
result
significantli
reduc
price
becom
afford
independ
supplier
technolog
sever
measur
perform
method
start
fragment
adapt
ligat
anneal
solidphas
amplif
slide
eg
illumina
emuls
amplif
bead
eg
roch
ion
torrent
requir
sequenc
exampl
fluoresc
nucleotid
illumina
ph
shift
ion
torrent
commenc
comput
align
data
analysi
complet
procedur
larg
autom
would
rational
blood
screen
expens
timeconsum
labour
amplif
result
directli
realtim
convent
nat
cost
far
higher
nat
alon
probabl
come
level
throughput
thousand
sampl
per
shift
still
challeng
sensit
yet
competit
altern
approach
would
highthroughput
digit
droplet
pcr
besid
high
number
differ
target
amplifi
parallel
reaction
time
reduc
minut
instead
hour
convent
pcr
howev
volum
process
nanolitr
rang
make
sensit
competit
digit
droplet
pcr
design
primarili
exact
quantif
high
sensit
blood
donat
screen
similar
shortcom
array
technolog
ng
digit
elisa
singlemolecul
array
simoa
quanterix
promis
time
sensit
convent
elisa
suffici
fast
capabl
alreadi
demonstr
detect
high
sensit
howev
concern
specif
highthroughput
autom
multipl
target
yet
avail
number
altern
nat
method
develop
mostli
isotherm
procedur
howev
none
develop
similar
matur
blood
screen
pcr
tma
advantag
sensit
specif
speed
multiplex
capabl
autom
level
cost
sinc
blood
donat
nat
alreadi
reach
ultim
goal
diagnost
detect
dnarna
molecul
present
reaction
tube
progress
probabl
made
around
groundbreak
technolog
may
includ
increas
multiplex
capabl
total
lab
autom
particularli
attract
big
blood
centr
thousand
sampl
per
day
smalland
mediums
blood
bank
small
benchtop
devic
high
flexibl
broad
rang
assay
use
patient
diagnost
blood
donor
screen
would
prefer
achiev
real
zero
transmiss
risk
transfus
medicin
would
requir
extract
nucleic
acid
least
ml
donor
plasma
minimum
volum
transfus
red
cell
sinc
one
copi
relev
virus
may
infecti
see
volum
must
reduc
small
amount
transfer
reaction
tube
without
loss
nucleic
acid
would
requir
highvolum
extract
method
repeat
test
small
volum
singl
sampl
technic
challeng
may
necessari
pathogen
reduct
also
succe
red
cell
would
suffici
appli
nat
abl
detect
donat
viral
load
exceed
inactiv
capac
respect
method
mini
pool
nat
moder
sensit
would
suffic
make
expens
singl
donat
nat
superflu
applic
method
donat
blood
would
enabl
us
reach
ultim
goal
zero
viral
risk
serolog
test
could
discontinu
similar
approach
could
envisag
bacteria
test
less
realist
bacteria
shown
grow
even
inactiv
low
number
surviv
spore
detect
nat
method
simpli
due
high
sampl
volum
need
screen
donat
bacteria
nat
would
thu
wast
time
resourc
bacteria
prefer
grow
platelet
may
long
lag
phase
start
exponenti
growth
would
advis
delay
test
bacteria
grown
higher
number
perform
test
late
possibl
compon
transfus
prereleas
bedsid
test
would
requir
fast
straightforward
method
prefer
take
minut
moder
sensit
limit
throughput
would
suffic
method
horizon
yet
readi
blood
screen
histori
blood
donat
nat
date
back
late
pcr
use
identifi
posttransfus
hcv
transmiss
rate
blood
compon
clot
factor
immunoglobulin
recipi
aid
hcv
epidem
trigger
worldwid
measur
increas
blood
safeti
made
concern
costbenefit
ratio
secondari
plasma
fraction
first
introduc
nat
test
product
pool
make
conjunct
pathogen
inactiv
blood
product
safe
possibl
achiev
similar
safeti
standard
blood
donat
centr
adopt
technolog
test
labil
compon
sinc
commerci
assay
avail
invest
high
amount
money
establish
inhous
nat
test
screen
donat
took
year
industri
develop
commerci
test
kit
suitabl
blood
screen
cover
suffici
broad
rang
transfusionrelev
virus
increas
autom
signific
price
reduct
made
technolog
amen
increas
number
countri
yield
serolog
neg
natonli
posit
donat
convinc
facilit
accept
viru
transmiss
risk
could
reduc
almost
zero
upon
introduct
univers
pathogen
reduct
conjunct
nat
test
ultim
goal
zero
risk
could
achiev
serolog
test
would
dispens
